Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis

Wentao Zhou, MD1,2, Dansong Wang, MD2, and Wenhui Lou, MD1

Abstract
Pancreatic cancer with synchronous liver metastasis has an extremely poor prognosis, and surgery is not recommended for such patients by the current guidelines. However, an increasing body of studies have shown that concurrent resection of pancreatic cancer and liver metastasis is not only technically feasible but also beneficial to the survival in the selected patients. In this review, we aim to summarize the short- and long-term outcomes following synchronous liver metastasectomy for pancreatic cancer patients, and discuss the potential criteria in selecting appropriate surgical candidates, which might be helpful in clinical decision-making.

Keywords
pancreatic cancer, liver metastasis, surgical resection, postoperative outcome, selecting criteria

Received July 15, 2020. Received revised November 02, 2020. Accepted for publication November 03, 2020.

Introduction
Pancreatic cancer (PC) is a lethal digestive system malignancy with a dismal 5-year survival rate of 9%.1 More than half of the PC patients are detected with distant metastases, of which liver is the most common site, accounting for 37%-41.9% of the initially diagnosed cases.2,3 PC patients with liver metastasis suffer from an extremely poor prognosis with a 5-year survival rate less than 1% and median overall survival (OS) of only 5 months.4 Currently, systemic chemotherapy is the optimal choice for most metastatic patients, and surgery is not recommended in the regular clinical practice by the guidelines. However, surgical resection of the liver metastasis has shown a significant improvement in the long-term survival for colorectal cancer, neuroendocrine tumor, and gastric cancer, which was also “neglected” in the previous treatments for these malignancies.5-7 Here we aim to discuss the role of surgery in PC patients with synchronous liver metastasis by reviewing the recent literature.

The Short- and Long-Term Outcomes Following Synchronous Liver Metastasectomy
The feasibility of synchronous pancreatectomy and heptectomy for metastatic PC has been verified in the most previous reports with mortality rates < 5% (Table 1).8-13 But Gleisner et al.14 reported that the 30-day postoperative mortality was up to 9.1% in the patients who underwent synchronous liver metastasectomy for peripanillary or pancreatic adenocarcinoma. This was significantly increased compared with 4.5% in the non-metastatic patients who underwent surgical resection, as well as 3% in the patients who underwent palliative bypass. Takada et al.15 observed the same high mortality in an earlier retrospective study, implying the potential risks of the combined surgery should be carefully evaluated even with the advancements in surgical techniques and perioperative managements.

Corresponding Authors:
Wenhui Lou, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Emails: lou.wenhui@outlook.com; lou.wenhui@zs-hospital.sh.cn
Dansong Wang, The Research Institution of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Email: wang.dansong@outlook.com
| Author (year) | No. of case | Size /no. of liver metastasis | Short-term outcome | Long-term outcome | Indication of hepatectomy |
|--------------|-------------|-------------------------------|-------------------|------------------|----------------------------|
| Takada et al (1997)¹⁵ | 15 | NA | Mortality: 9.1% | Recurrence rate: 100% | OS: 6 m |
| Yamada et al (2006)⁶ | Total: 6 | Size for total: 2.6 cm³ | Mortality for total: 33.3% | Recurrence rate for total: 80% | 1. Complete excision of intrahepatic disease |
| | SR: 5 | No.: NA | Mortality for total: 0 | 1-year OS rate for total: 66.7% | 2. Extirpation of primary disease |
| | MR: 1 | | | 3-year OS rate for total: 33.3% | 3. No extrahepatic diseases |
| Shrikhande et al (2007)⁹ | Total: 29 | NA | Morbidity for total: 24.1% | OS for total: 13.8 m | 1. Patient in good general condition |
| | Liver met: 11 | | Mortality for total: 0 | 1-year OS rate for total: 58.9% | 2. Patient’s preference for resection |
| | Extrahepatic met: 18 | | | OS for liver met: 11.4 m | 3. Peripherally located 1 or 2 liver met |
| | | | | | 4. Impression of “low overall tumor burden” |
| | | | | | 5. High probability of R0 resection |
| | | | | | 6. ASA grade ≤ III |
| Gleisner et al (2007)¹⁴ | Total: 22 | Size for total: 0.6 cm³ | Morbidity for total: 45.5% | DFS for total: 3.2 m | NA |
| | PC: 17 | No. for total: 1ᵃ | Mortality for total: 9.1% | OS for PC: 5.9 m | |
| | Periampullary cancer: 5 | | | 1-year OS rate for total: 13.3% | |
| Düünschede et al (2010)¹⁰ | 9 | Size: 3.5 cmᵇ | Mortality: 33% | OS: 8 m | NA |
| | No.: 3ᵃ | | Mortality: 0 | | |
| de Jong et al (2010)¹¹ | Total: 20 | Size for total: 0.6 cm³ | Morbidity for total: 30% | OS for total: 13 mᶜ | NA |
| | SR: 14 | No. for total: 1ᵃ | Mortality for total: 0 | 3-year OS rate for total: 8%ᶜ | |
| Klein et al (2012)¹² | 22 | NA | Morbidity: 18% | OS: 7.6 m | Considering the local resectability and comorbidity by the surgeon in a case-by-case evaluation |
| | | | Mortality: 0 | 1-year OS rate: 32% | |
| Bahra et al (2015)¹³ | Total: 45 | NA | Morbidity for total: 20% | OS for total: 10.4 m | NA |
| | SR: 2¹ | | Mortality for total: 2% | 1-year OS rate for total: 38% | |
| | Pancreatectomy only: 24 | | | 2-year OS rate for total: 11% | |
| Zanini et al (2015)¹⁶ | Total: 15 | Size for total: 2.2 cm³ | Morbidity for total: 60% | DFS for total: 5.2 m | 1. Patient in good condition, fit for surgery |
| | SR: 1¹ | No. for total: 1ᵃ | Mortality for total: 0 | OS for SR: 8.3 m | 2. Small, single or few metastases |
| | MR: 4 | | | | 3. Feasible excision of all intrahepatic metastases, low surgical risk, and high probability to obtain a R0 resection |
| | | | | | 4. Resectable primary tumor |
| | | | | | 5. No evidence of extrahepatic disease |
| Tachezy et al (2016)¹⁷ | 69 | Size: NA | Mortality: 68% | OS: 14.5 m | 1. ASA classification ≤ III |
| | No.: 2ᵃ | | Mortality: 1% | 5-year OS rate: 5.8% | 2. Patient’s strong preference for operation |
| Shi et al (2016)¹⁸ | 30 | NA | Mortality: 0 | OS: 15.7 m | 1. Intention to reach a R0 status |
| | | | | | 2. ASA classification ≤ III |

(continued)
| Author (year)            | No. of case | Size /no. of liver metastasis | Short-term outcome | Long-term outcome       | Indication of hepatectomy                                                                 |
|-------------------------|-------------|-------------------------------|-------------------|------------------------|-------------------------------------------------------------------------------------------|
| Hackert et al (2016)    | Total: 85   | Size for total: 43% < 1 cm, 31.7% 1-2 cm | Morbidity for SR: 45%<sup>d</sup> | OS for SR: 10.6 m      | NA                                                                                         |
|                         | SR: 62      | No. for total: 96.4% ≤ 3 m   | Mortality for SR: 1.6% | 5-year OS rate for total: 8.1% | NA                                                                                         |
|                         | MR: 23      |                               |                   |                        |                                                                                            |
| Wright et al (2016)     | Total: 23   | SR: 9                         | Morbidity for total: 13% | DFS for total: 8.6 m   | 1. Resectable or borderline resectable primary pancreatic tumor                             |
|                         |             | Pancreatectomy only or with resection of extrahepatic met: 14 | Mortality for total: 0 | OS for total: 18.2 m   | 2. Major biochemical response to chemotherapy                                             |
|                         |             |                               |                   | 1-year OS rate for total: 72.7% | 3. Complete or major radiological response of liver metastases with one remaining metastasis |
|                         |             |                               |                   | 3-year OS rate for total: 21.5% |                                                                                            |
| Crippa et al (2016)     | Total: 11   | SR: 3                         | Morbidity for total: 27% | Recurrence for total: 90.9% |                                                                                            |
|                         |             | Pancreatectomy only: 8        | Mortality for total: 0 | OS for total: 39 m     |                                                                                            |
| Andreou et al (2018)    | Total: 76   | Size: 1 cm<sup>a</sup>        | Morbidity: 50%     | 5-year DFS rate: 5%   | 1. Possibility of safe removal of liver metastases                                        |
|                         |             | No.: 1<sup>a</sup>           | Mortality: 5%      | 5-year OS rate: 7%    | 2. Sufficient liver remnant                                                                |
|                         |             |                               |                   | OS for total: 7.8 m   | 3. No extrahepatic metastases                                                              |
|                         |             |                               |                   | 1-year OS rate for total: 31.3% | 4. High probability of R0 resection of primary pancreatic tumor                           |
|                         |             |                               |                   | 3-year OS rate for total: 4.2% | 5. Completely extirpation of liver metastases                                              |
|                         |             |                               |                   |                        | 6. ASA score ≤ III                                                                        |
| Yang et al (2019)       | Total: 48   | Size for non-/oligometastatic SR: 25 | Morbidity for non-/oligometastatic SR: 16% / 13% | OS for total: 7.8 m   |                                                                                            |
|                         |             |                               | Mortality for non-/oligometastatic SR: 8% / 0 | 1-year OS rate for total: 31.3% |                                                                                            |
|                         |             |                               |                   | 3-year OS rate for total: 4.2% |                                                                                            |
|                         |             |                               |                   |                        |                                                                                            |

ASA, American Society of Anesthesiologists; DFS, disease-free survival; m, months; MR, metachronous resection; met, metastasis; NA, not available; OS, overall survival; PC, pancreatic cancer; SR, synchronous resection; <sup>a</sup>, median; <sup>b</sup>, mean; <sup>c</sup>, calculated in the patients with pancreatic (n = 20) and distal bile duct tumors (n = 5); <sup>d</sup>, calculated in the synchronously resected patients for liver metastasis (n = 62) and inter-aortocaval lymph node metastasis (n = 43).
The postoperative morbidity rates varied greatly in the published studies.  
Tachezy et al. reported the highest morbidity rate of 68% for synchronous resection by analyzing liver metastatic PC cases from 6 European pancreas centers, which was significantly elevated compared with that in the non-resected patients but comparable to the published data on patients with pancreatic resection only. In the study including the most synchronous resection cases, Andreou et al. reported the overall morbidity rate of 50% and major morbidity rate of 16%. Many factors, such as the patient conditions, resection extents, and surgeon techniques, could affect the complications following pancreatectomy alone or combined with hepatectomy. The majority of the previous studies on the synchronous resections for liver metastatic PC indicated that the postoperative morbidity rates were acceptable in comparison to the internal control groups and the reported data. The survival benefit of PC patients with liver metastasis is the major concern for surgeons to make therapeutic decisions. The median OS following synchronous liver metastasectomy and pancreatectomy for PC ranged from 5.9 to 15.7 months in the literature. After analyzing 14 cases, Dünschede et al. found that the median survival of the patients who underwent concurrent resection was not superior to that of those receiving chemotherapy (8 vs. 11 months). Thus, the authors did not recommend the synchronous resection of PC and liver metastasis. Disappointing survival outcomes following synchronous resection brought about the similarly negative conclusions in some other studies as well. But Tachezy et al. took a different view by the analysis of 69 cases. They showed that patients who underwent combined pancreatic and hepatic resection obtained the notably improved OS compared with the unresected patients (14.5 vs. 7.5 months, P < 0.001), with acceptable morbidity and mortality. Likewise, in the other 2 studies containing 76 and 62 synchronous resected cases, the 5-year OS rates were up to 7% and 8.1%, respectively. Concurrent surgical resection for PC patients with liver metastasis has been supported by an increasing number of surgeons, particularly for the highly selected cases. So, the current challenge may turn to how to select suitable surgical candidates.

**Burden of Liver Metastasis**

Tumor burden predicts the prognosis of patients with metastatic malignancies. An early systemic review performed by Michalski et al. indicated that the long-term survival in PC patients who underwent concurrent resection for one or few liver metastases was comparable to the cases without evidence of metastasis. Recently, Tachezy et al. considered that PC patients with a small metastatic tumor burden could benefit from this aggressive surgery even without preoperative chemotherapy, on account of the result that the median OS in the patients with isolated liver metastasis (n = 65) was greatly prolonged in comparison to that in the patients with ≥2 metastases (n = 73) (11.6 vs. 5.6 months, P < 0.005). Zanini et al. believed that both the number of liver metastases (single vs. multiple) and the diameter of the largest metastatic lesion (<2 vs. ≥2 cm) had detrimental effects on the survival. But in the study of liver oligometastatic PC undergoing curative resection, Hackert et al. showed that neither the number (1 vs. 2 vs. ≥3, P = 0.589) nor the size of liver metastases (<1 vs. ≥1 cm, P = 0.713) had an influence on the OS. Similar analysis conducted by Andreou et al. also demonstrated that the number of liver metastases (1 vs. 2-5, P = 0.922) was not associated with the OS in the oligometastatic patients who received synchronous resection. The above evidence may suggest that oligometastasis, a clinical state between localized and widespread metastatic disease, could be a potential criterion for selecting surgical candidates. The further key point is how to accurately define “oligometastasis” for PC patients, which was initially described as metastases limited in number and concentrated to a single or limited organs by Hellman and Weichselbaum in 1995.

**Neoadjuvant Chemotherapy**

Neoadjuvant chemotherapy has been paid much attention to in the borderline resectable and resectable PC for its potential advantages: degrading tumor stage to improve resection rate, eliminating micrometastasis to prevent early recurrence, and guiding postoperative chemotherapy. Though neoadjuvant chemotherapy for metastatic PC patients was explored much less, some recent studies have shown promising results. Wright et al. reported 23 metastatic patients (liver metastasis, n = 16) who underwent pancreatectomy with or without metastasectomy (liver metastasectomy, n = 9) after favorable response to chemotherapy. The study indicated that the median OS from surgery and disease-free survival (DFS) and OS from diagnosis were 18.2, 8.6 and 34.1 months, respectively. Crippa et al. also reported 11 liver metastatic PC patients who underwent either primary or combined resection following complete or partial response to chemotherapy, and these patients obtained significantly longer OS than the liver metastatic cases receiving palliative chemotherapy (n = 116) (39 vs. 11 months, P < 0.0001) and those without resection after partial response (n = 42) (39 vs. 12 months, P < 0.0001). A more recent study from Frigerio et al. showed that the OS and DFS for
synchronous liver metastatic PC patients who underwent pancreatectomy after downstaging following chemotherapy \((n = 24)\) were up to 56 months and 27 months, respectively, which seemed to be even better than the prognosis of many non-metastatic resected patients. These favorable results affirmed the positive effects of neoadjuvant chemotherapy in selecting potential patients who could benefit from the operation. Yet, it is necessary to conduct large-scale prospective studies since the current viewpoints were drawn from the limited retrospective case reports or case series. Furthermore, the chemotherapy regimen, efficacy assessment, and surgical intervention timing need to be clarified in detail.

**Tumor Markers**

Serum carbohydrate antigen 19-9 (CA19-9) has been a useful marker in the evaluation of resectability and prognosis for resectable and borderline resectable PC with different cut-off points, which implies its potential value in selecting suitable metastatic PC candidates for surgical resection.\(^{12,34}\) Crippa et al.\(^{21}\) reported that CA19-9 reduction < 50% of baseline level after chemotherapy was an independent risk factor of OS in the liver metastatic patients following resection. They thought that major biochemical response (CA19-9 decrease > 90%), as a complementary evaluation to the radiologic response, should be a required condition for surgery. Carbohydrate antigen 125 (CA125) was also reported as an important biomarker for synchronous liver metastatic PC by Shi et al.\(^{18}\) They found that this marker could be used not only in the evaluation of resectability for synchronous liver metastasis but also in the prognostic prediction following this combined resection, indicating its supportive value in Lewis-negative individuals, who secrete very little CA19-9.

**Pancreatic Cancer Location**

Recently, Yang et al.\(^{23}\) retrospectively analyzed their single-center experience of 23 liver oligometastatic PC cases with synchronous resection. They showed that the OS of patients with pancreatic head cancer who underwent synchronous resection did not differ from that of the systemic chemotherapy counterparts (6.9 vs. 5.6 months, \(P = 0.75\)), whereas patients with pancreatic body/tail cancer undergoing synchronous resection had improved OS compared with those receiving chemotherapy (16.8 vs. 8 months, \(P = 0.03\)). But controversial results could be discovered in an early study. Tachezy et al.\(^{17}\) reported that the pancreatic head cancer had better median OS in liver oligometastatic patients who received concurrent resection than in those requiring no resection (14.5 vs. 7 months, \(P < 0.001\)), whereas no difference existed in the OS between resection and non-resection patients with oligometastatic pancreatic body/tail cancer (14 vs. 12 months, \(P = 0.198\)). It was hard to judge whose conclusions were more persuasive since the 2 studies not only adopted distinct inclusion criteria and therapeutic strategies, but also reviewed relatively few cases. Given the surgical risk and postoperative quality of life, pancreatic body/tail cancer with oligometastasis still be a prior choice for surgery.

To date, no prospective research with regard to synchronous resection of liver metastatic PC has been published. Several previous studies mentioned their general indications of hepatectomy, but these indications might not be of great referential value in selecting the suitable cases (Table 1). Currently, 2 ongoing studies could be found in the ClinicalTrials.gov database, both of which take liver metastases \(\leq 3\) as a resection criterion (Table 2). In addition, Yu et al focus on the role of chemotherapy in screening the potential candidates in a large

### Table 2. Ongoing Clinical Studies on Synchronous Resection for PC With Liver Metastasis.

| Researcher | Country | Estimated participant | Major criteria of hepatectomy | Primary outcome | Secondary outcome |
|------------|---------|-----------------------|-------------------------------|----------------|-------------------|
| Zani et al | United States | 15 | 1. Suitable candidate for surgery 2. Liver metastases \(\leq 3\) | 1. 90-day mortality 2. Disease progression 3. Overall survival | 1. Postoperative length of stay 2. Frequency of pancreatic leak 3. Readmission to hospital 4. Margin status 5. Lymph node status 6. Time to adjuvant therapy 7. Operation room time 8. Intraoperative estimated blood loss |
| Yu et al   | China   | 300 | 1. ECOG 0 -1 2. Liver metastases \(\leq 3\) 3. No extrahepatic metastases 4. Resectable primary and metastatic tumor 5. No new metastasis after chemotherapy 6. \(\geq 50\%\) reduction of tumor maker after chemotherapy 7. No contraindication of operation | Real overall survival | 1. Overall survival 2. Life quality score 3. Postoperative morbidity 4. Postoperative mortality |

ECOG, Eastern Cooperative Oncology Group; PC, pancreatic cancer.
cohort of 300 estimated participants, which deserves to look forward to.

**Conclusion**

A growing body of evidence supports the role of synchronous resection in the selective PC patients with liver metastasis. But no consensus has been successfully reached for selecting appropriate surgical candidates. The current major concerns on patient selection include the metastatic tumor burden, chemotherapeutic efficacy, tumor marker level, as well as candidates’ health condition. We think liver oligometastatic PC patients, achieving major radiological and biochemical responses to neoadjuvant chemotherapy, could be suitable for further resections, particularly for whose primary tumor located at the pancreatic body/tail. All the previous results regarding surgery in the liver metastatic PC came from retrospective studies, where the included cases were quite limited and highly heterogeneous. Registry studies, especially with nationwide cooperation, should be able to provide a mass of patients for more efficient analysis before starting randomized controlled trials.

**Abbreviations**

CA125, Carbohydrate Antigen 125; CA19-9, Carbohydrate Antigen 19-9; DFS, Disease-free Survival; OS, Overall Survival; PC, Pancreatic Cancer.

**Acknowledgments**

The authors thank Dr. Ashely Shin for her helpful assistance in the language polishing.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Shanghai Municipal Health Commission (No.201840190).

**ORCID iD**

Dansong Wang, MD ☑️ https://orcid.org/0000-0002-8406-3222
Wenhui Lou, MD ☑️ https://orcid.org/0000-0001-5820-6843

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. van der Geest LGM, Lemmens V, de Hingh I, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017;104(11):1568-1577.
3. Maire F, Cibot JO, Compagne C, et al. Epidemiology of pancreatic cancer in France: descriptive study from the French National Hospital Database. Eur J Gastroenterol Hepatol. 2017;29(8):904-908.
4. Kneuertz PJ, Cunningham SC, Cameron JL, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917-1927.
5. Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270-4277.
6. Silberhumer GR, Paty PB, Denton B, et al. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery. 2016;160(1):67-73.
7. Tapia Rico G, Townsend AR, Klevansky M, Price TJ. Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path? Expert Rev Anticancer Ther. 2016;16(12):1219-1225.
8. Yamada H, Hirano S, Tanaka E, Shichinohe T, Konno S. Surgical treatment of liver metastases from pancreatic cancer. HPB (Oxford). 2006;8(2):85-88.
9. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118-127.
10. Dunschede F, Will L, von Langsdorf C, et al. Treatment of simultaneous and synchronous liver metastases of pancreatic cancer. Eur Surg Res. 2010;44(3-4):209-213.
11. de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102(3):256-263.
12. Klein F, Puhl G, Guckelberger O, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012;2012:939350.
13. Bahra M, Pratschke J, Klein F, et al. Cytoreductive surgery for pancreatic cancer improves overall outcome of gemcitabine-based chemotherapy. Pancreas. 2015;44(6):930-936.
14. Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of peripanillary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484-2492.
15. Takada T, Yasuda H, Amano H, Yoshida M, Uchida T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology. 1997;44(14):567-573.
16. Zanini N, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 2015;67(1):19-25.
17. Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136-144.
18. Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: diagnosis and assessment of unresectability. World J Gastroenterol. 2016;22(45):10024-10037.
19. Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(2):358-363.
20. Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. *J Gastrointest Surg*. 2016;20(11):1830-1835.

21. Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? *Eur J Surg Oncol*. 2016;42(10):1533-1539.

22. Andreou A, Knitter S, Klein F, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. *Surg Oncol*. 2018;27(4):688-694.

23. Yang J, Zhang J, Lui W, et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. *HPB (Oxford)*. 2020;22(1):91-101.

24. Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. *ANZ J Surg*. 2016;86(12):973-977.

25. Nentwich MF, Bockhorn M, König A, Izbicki JR, Cataldegirmen G. Surgery for advanced and metastatic pancreatic cancer—current state and trends. *Anticancer Res*. 2012;32(5):1999-2002.

26. Ghidini M, Petrillo A, Salati M, et al. Surgery or locoregional approaches for hepatic oligometastatic pancreatic cancer: myth, hope, or reality? *Cancers (Basel)*. 2019;11(8):1-16.

27. Michalski CW, Erkan M, Huser N, et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. *Dig Surg*. 2008;25(6):473-480.

28. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol*. 1995;13(1):8-10.

29. Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant treatment for pancreatic cancer. *Semin Oncol*. 2019;46(1):19-27.

30. Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. *J Clin Oncol*. 2017;35(5):515-522.

31. Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? *Ann Surg Oncol*. 2017;24(8):2397-2403.

32. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. *Ann Surg Oncol*. 2013;20(7):2188-2196.

33. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. *Eur J Surg Oncol*. 2007;33(3):266-270.

34. Li J, Li Z, Kan H, et al. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. *Pancreatology*. 2019;19(2):302-326.